Mark Stejbach
Director/Board Member chez INDIVIOR PLC
Fortune : 271 431 $ au 31/03/2024
Profil
Mark P.
Stejbach is an Independent Non-Executive Director at Indivior PLC since 2021.
He was previously an Independent Director at Flexion Therapeutics, Inc. from 2016 to 2021, a Director at Commonwealth National Fund, Inc. from 2003 to 2011, a Principal at Biogen MA, Inc. in 1997, and a Vice President-Managed Care Marketing at Merck & Co., Inc. from 1987 to 2008.
He also served as the Chief Commercial Officer & Head-Media Relations at Tengion, Inc. in 2011 and as the Chief Commercial Officer & Senior Vice President at Alkermes Plc from 2012 to 2018.
Stejbach received his undergraduate degree from Virginia Polytechnic Institute & State University and his MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INDIVIOR PLC
0,01% | 01/03/2024 | 12 684 ( 0,01% ) | 271 431 $ | 31/03/2024 |
Postes actifs de Mark Stejbach
| Sociétés | Poste | Début |
|---|---|---|
| INDIVIOR PLC | Director/Board Member | 24/03/2021 |
Anciens postes connus de Mark Stejbach
| Sociétés | Poste | Fin |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
| ALKERMES PLC | Corporate Officer/Principal | 01/10/2018 |
| TENGION, INC. | Public Communications Contact | 01/01/2012 |
Commonwealth National Fund, Inc.
 Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Director/Board Member | 01/01/2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2008 |
Formation de Mark Stejbach
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| TENGION, INC. | Health Technology |
| INDIVIOR PLC | Health Technology |
| ALKERMES PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Finance |
